Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marija Balic

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2026
Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative StudiesNeil Carleton, Alexander C Chang, Fangyuan Chen, et al.
NEJM Evidence|February 6, 2024
Long-Term Outcomes of Adjuvant Denosumab in Breast CancerMichael Gnant, Sophie Frantal, Georg Pfeiler, et al.
Cancer Communications (London, England)|January 6, 2025
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXdChristian Fridolin Singer, Stephan Wenzel Jahn, Dominik Hlauschek, et al.
Nature Cancer|January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
The New England Journal of Medicine|July 28, 2021
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast CancerMichael Gnant, Florian Fitzal, Gabriel Rinnerthaler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)Erica L Mayer, Christian Fesl, Dominik Hlauschek, et al.
NPJ Breast Cancer|February 20, 2026
Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programsGitte Zels, Karen Van Baelen, Alexander Cc Chang, et al.
Breast Cancer Research : BCR|June 19, 2025
Hope for OTHERS (Our Tissue Helping Enhance Research & Science): research results from the University of Pittsburgh rapid autopsy program for breast cancerAlexander Chih-Chieh Chang, Marija Balic, Tanner Bartholow, et al.
Biorxiv : the Preprint Server for Biology|November 22, 2024
Hope for Others: Research Results from the University of Pittsburgh Rapid Autopsy Program for Breast CancerAlexander Chih-Chieh Chang, Marija Balic, Tanner Bartholow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2023
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS TrialGeorg Pfeiler, Dominik Hlauschek, Erica L Mayer, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2026
Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative StudiesNeil Carleton, Alexander C Chang, Fangyuan Chen, et al.
NEJM Evidence|February 6, 2024
Long-Term Outcomes of Adjuvant Denosumab in Breast CancerMichael Gnant, Sophie Frantal, Georg Pfeiler, et al.
Cancer Communications (London, England)|January 6, 2025
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXdChristian Fridolin Singer, Stephan Wenzel Jahn, Dominik Hlauschek, et al.
Nature Cancer|January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
The New England Journal of Medicine|July 28, 2021
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast CancerMichael Gnant, Florian Fitzal, Gabriel Rinnerthaler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)Erica L Mayer, Christian Fesl, Dominik Hlauschek, et al.
NPJ Breast Cancer|February 20, 2026
Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programsGitte Zels, Karen Van Baelen, Alexander Cc Chang, et al.
Breast Cancer Research : BCR|June 19, 2025
Hope for OTHERS (Our Tissue Helping Enhance Research & Science): research results from the University of Pittsburgh rapid autopsy program for breast cancerAlexander Chih-Chieh Chang, Marija Balic, Tanner Bartholow, et al.
Biorxiv : the Preprint Server for Biology|November 22, 2024
Hope for Others: Research Results from the University of Pittsburgh Rapid Autopsy Program for Breast CancerAlexander Chih-Chieh Chang, Marija Balic, Tanner Bartholow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2023
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS TrialGeorg Pfeiler, Dominik Hlauschek, Erica L Mayer, et al.
Pageof 13